KCL-HO-1i: A Novel HO-1 Inhibitor Targeting Tumor-Associated Macrophages
/0 Comments/in Preclinical Research/by MaxNewsletter 32/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week’s newsletter is more concise, spotlighting clinical trials over preclinical research. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. For more details on […]
New Bacterial Therapy Destroys Tumors in Immunocompromised Animal Models
/0 Comments/in Oncolytic, Preclinical Research/by MaxPhase 2 trial: Tarlatamab for Neuroendocrine Prostate Cancer (NEPC)
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase Ib/II Study of TYK-00540 Combined With Enzalutamide in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase Ib/II Clinical Trial of TY-302 and Abiraterone Acetate in mCRPC
/0 Comments/in Clinical Trial, Phase 1, Phase 2/by MaxFDA Clears First-in-Human Trial of NSD2 Inhibitor in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 31/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week we had several updates in both clinical trials and preclinical research. I had to keep an eye on the newsletter’s length! Stay strong and fight on! As usual, we also have a podcast if you prefer to […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial theranostics
Latest Posts
- Newsletter 37/2025 September 14, 2025
- OST-504: A Novel Immunotherapy Targeting Prostate Cancer September 13, 2025
- Memantine Shows Promise Against Advanced Prostate Cancer September 11, 2025
- Pasritamig in Late-Line Prostate Cancer: From Early Findings to the KLK2-comPAS Trial September 11, 2025